ARTICLE | Company News
With industry's growing kidney momentum, Everest begins building kidney portfolio
June 10, 2019 6:04 AM UTC
Everest Medicines added its first therapy to a planned renal portfolio on Monday through a deal with Calliditas.
The therapy, Nefecon (PL-56, Nefigan), is in the Phase III Nefigard trial to treat IgA nephropathy. It is an enteric formulation of budesonide that down-regulates the kidney's inflammatory process...